Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
US9598703B2 · kind B2 · utility
43Cited by
0References
17Claims
0Family size
Assignees
- ASSOCIATION INSTITUT DE MYOLOGIE; UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTÉ DE LAD RECHERCHE MÉDICALE
- THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
Inventors
Key dates
| Filing date | Mar 12, 2012 |
| Grant date | Mar 21, 2017 |
| Priority date | — |
| Expiry date | Oct 11, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An isolated linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest and a second AAV ITR, wherein said nucleic acid molecule is devoid of AAV capsid protein coding sequences. The said nucleic acid molecule can be applied to a host at repetition without eliciting an immune response. Methods for producing and purifying this nucleic acid molecule, and use of the same for therapeutic purposes are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.